Close Menu

People in the News

Jan 15, 2020

AACC: Janet Kreizman

American Association of Clinical Chemistry CEO Janet Kreizman is retiring from the organization in the second quarter of 2020, the organization said. She has been with AACC for almost seven years. During her tenure, AACC created a first-of-its kind point-of-care testing professional certification and the launch of its second peer-reviewed journal, AACC noted. Prior to joining AACC, she was the deputy executive director and chief policy officer at the Endocrine Society, according to her LinkedIn profile. AACC's board is organizing the search process for a new CEO. 

Jan 14, 2020

Geneoscopy: Mark Van Cleve

Geneoscopy has appointed Mark Van Cleve its vice president of product development. He has more than 25 years of experience in the design and development of in vitro diagnostic products and technologies and was most recently head of R&D, Clinical Lab Menue at Ortho Clinical Diagnostics. Before that, he was VP of R&D at Hycor Biomedical. He has also held positions at Agilent Technologies, Chiron, and BD Biosciences. 

Jan 14, 2020

Myriad Genetics: Thomas Slavin

Thomas Slavin will be senior VP of medical affairs at Myriad Genetics' oncology division. Starting March 2, he will report to Nicole Lambert, president of Myriad Oncology, and be in charge of Myriad's portfolio of molecular and companion diagnostic products and services for oncology. Slavin is board certified in clincial genetics, medical diagnostics, and pediatrics, and most recently was an assistant professor in City of Hope National Medical Center's medical oncology & therapeutics research and population sciences division. 

Jan 13, 2020

T2 Biosystems: Tony Pare

T2 Biosystems has promoted Tony Pare to the newly created position of chief commercial officer, effective immediately. Pare previously served as vice president and general manager of T2 Biosystems' international business. Prior to that, he held senior business development positions at Haemonetics and Hemanext.

Jan 13, 2020

Spartan Bioscience: Dirk Sibbing; Gilles Montalescot; Marco Valgimigli; Davide Capodanno

Spartan Bioscience has establishd a scientific advisory board in Europe. The members are Dirk Sibbing, an inverventional cardiologist and professor of cardiology at Ludwig-Miximilians University in Munich; Gilles Montalescot, a professor of cardiology at the University of Paris VI, and director of the cardiac care unit at Pitié-Salpêtrière Hospital, Paris; Marco Valgimigli, associate professor of cardiology and senior interventional cardiology at Inselspital Universitätsspital in Bern, Switzerland; and Davide Capodanno, associate professor of cardiology at the University of Catania, Italy, and interventional cardiologist, Azienda ""Policlinico-Vittorio Emanuele" in Catania. The company added that a North American team will be announced in March at the American College of Cardiology conference. 

 
Jan 13, 2020

Foundation Medicine: Ritesh Khullar

Ritesh (Tesh) Khullar has been appointed as chief commercial officer of Foundation Medicine, effective Jan. 20. He joins the Roche subsidiary from Flatiron Health, where he was responsible for leading and scaling provider service offerings. Prior to that, he was the national VP and general manager of sales and account management at McKesson Specialty Health. He also held various roles at Oncology Therapeutics Network. Khullar holds an MBA from the University of San Francisco and a BA in history with a minor in computer science and engineering, political science, and law and society from the University of California, San Diego.

Jan 09, 2020

T2 Biosystems: John Sperzel, John McDonough

T2 Biosystems has appointed John Sperzel as president, CEO, and board member. He succeeds John McDonough, T2 Bio's outgoing president and CEO, who will serve as non-executive chairman of the board.

Sperzel has resigned as Chembio Diagnostics' president and CEO. Prior to Chembio, Sperzel served as president and CEO of ITC Medical, a privately-held point-of-care diagnostics company owned by Warburg-Pincus. Previously, Sperzel held executive and commercial leadership positions at Axis-Shield, Bayer Diagnostics, Instrumentation Laboratory, and Boehringer Mannheim.

Jan 09, 2020

Chembio Diagnostics: Gail Page

Chembio Diagnostics has appointed Gail Page, a company director, as its interim CEO and has initiated an executive search to identify a permanent CEO. John Sperzel has resigned as Chembio's president and CEO and replaced John McDonough as T2 Biosystems' president and CEO.

Page has served on Chembio's board of directors since 2017. She is a venture partner at Turret Capital Management and was previously president and CEO at Vermillion. Further, she served as chief operating officer of Luminex for three years and Roche Biomedical Laboratories, which is now Laboratory Corporation of America, for 12 years.

Jan 09, 2020

Todos: Gerald Commissiong, Daniel Hirsch

Todos Medical announced it appointed Gerald Commissiong as CEO and Daniel Hirsch as CFO. The company's former CEO, Herman Weiss, will stay on as the chairman of the board of directors. Commissiong is currently the president and CEO of Amarantus Bioscience Holdings and is the interim CEO of Breakthrough Diagnostics, the joint venture between Todos and Amarantus. He previously played football for the Calgary Stampeders of the Candian Football League and received his degree in management science and engineering from Stanford University.

Hirsch has spent 25 years of experience with public companies and a background in investor relations. Both executives will oversee Todos' relocation from Israel to the US. 

Jan 09, 2020

BioDirection: Jean-Luc Boulnois

BioDirection announced that Jean-Luc Boulnois has joined its board of directors.

Boulnois is the president and CEO of Quadrature, an advisory firm in the medical devices space. He has prevously developed early-stage companies, participated in an initial public offering, and led mergers, acquisitions, and financing rounds. Boulnois was involved with Microline Surgical for more than 18 years, first as an investor and later as CEO and executive chairman.

He has held senior-level positions at Dover Medical Ventures, Interactive Consulting, Sometec, Technomed International, and Arrow International. Boulnois serves on the boards of Fineheart, NidoSurgical, and Biomodex. 

Jan 08, 2020

Opko: Anthony Japour

Opko Health announced that its board appointed Anthony Japour as a new director, effective Jan. 6, until the company's 2020 annual stockholder meeting. Japour has been the medical director at Icon, a development outsourcer for the pharmaceutical, biotechnology, and medical devices industries, since 2016. He has also been the principal of consulting company Anthony Japour and Associates, Medical and Scientific Consulting since 2006. From 2012 to 2016, Japour was a physician at Elite Health Medical Group and South Florida Cardiology Associates. He is also a director for Cocrystal Pharma. 

Jan 08, 2020

Abbott: Brian Yoor, Robert Funck

Abbott announced Brian Yoor, the company's CFO and executive vice president, finance, will retire on Feb. 29, 2020. Yoor has been in his position since February 2017. Robert Funck will take over those roles on March 1. Funck has worked at Abbott since 1987 and served as the senior VP, finance. He has been Abbott's controller since 2013 and was VP, chief ethics and compliance officer from 2009 to 2013; VP, internal audit between 2007 and 2009; and VP and treasurer from 2005 to 2007. 

Jan 08, 2020

Cytox: Ian Gilham

Cytox has appointed Ian Gilham its chairman of the board. He was CEO of Axis-Shield until Alere acquired the company in 2011. He also held positions at Amersham International, Abbott Laboratories, and GlaxoSmithKline. Gilham is currently non-executive chairman of Horizon Discovery, Genedrive, and Biosurfit and previously was chairman of Multiplicom and Elucigene. Oxford, UK-based Cytox develops noninvasive risk assessment and patient stratification tools for Alzheimer's disease and dementia. 

Jan 07, 2020

Quotient Limited: Peter Buhler, Ed Farrell

Commercial-stage diagnostics company Quotient Limited announced the appointment of Peter Buhler as CFO, replacing current CFO Chris Lindop, who plans to retire in May 2020. The company said Buhler would take over CFO duties on Feb. 5, while Lindop transitions to Executive VP. Buhler was previously the Group CFO at Zaluvida and has 20 years of experience in financial and strategic roles in the life sciences and technology businesses, including at Stallergenes Greer, Logitech, and Merck Serono. 

Quotient also announced that Ed Farrell would be the company's new COO. Farrell was previously the company's president and has been a senior executive at the company since 2013. He led the MosaiQ research and development activities and established the company's microarray facility. 

Jan 07, 2020

Bio-Rad: Dara Grantham Wright

Bio-Rad Laboratories has appointed Dara Grantham Wright executive vice president and president of the Clinical Diagnostics Group, effective Jan. 1. She replaces John Hertia, who retired from the role on Dec. 31, 2019. Grantham Wright was most recently VP and GM, Biosciences division, Life Science Solution group, Protein & Cell Analysis at Thermo Fisher Scientific. Prior to that, she was SVP and GM of the eBioscience business unit at Affymetrix, now part of Thermo Fisher. She also served as global VP of strategic marketing and clinical applications at Affymetrix and was chief commercial officer at Boreal Genomics.  

Jan 07, 2020

ArcherDx: Mark Massaro

ArcherDx has appointed Mark Massaro its CFO. He was most recently managing director and senior research analyst covering the diagnostics and life science tools sector at investment bank Canaccord Genuity. He also held corporate finance and financial reporting positions at Dell EMC and Fidelity Investments. 

Jan 06, 2020

NuProbe Global: Yingshuang Chai

NuProbe Global has named Yingshuang Chai CEO and chairman of the board of directors. Chai was cofounder and CEO of CarrierGene Biotech, a Chinese genetic testing firm that recently merged with NuProbe. He brings 20 years of experience in market operations, having served as the national clinical business director at Life Technologies China and national director of clinical strategy and development at Thermo Fisher China.

Jan 02, 2020

Inspirata: Oenone Duroe

Inspirata has appointed Oenone Duroe its general manager of Europe. She will be based in Maidenhead, UK and oversee Inspirata's operations in the UK, Ireland, and the Nordic region, as well as in Austria, Germany, and Switzerland. Oenone was most recently external GM, UK and Ireland for Daiichi-Sankyo. She previously was at Proteus Digital Healthcare, where she developed reproducible reimbursement streams, and at Novo Nordisk. 

Dec 31, 2019

Enzo Biochem: Rebecca Fischer

Enzo Biochem has appointed Rebecca Fischer to its board of directors, effective immediately. Her appointment as an independent director follows a process as part of the company's focus on board compositions, refreshment, and diversity. Fisher's appointment, Enzo said, will be a valuable contribution to its women's health business. She replaces Gregory Bortz who retired from the board. Dov Perlysky, who has been on the board since 2012, will replace Bortz as lead independent director of Enzo. 

Fisher has been appointed to Enzo's audit, compensation, and nominating/governance committees and will be chair of the audit committee. She is currently CFO of Bellevue Hospital. She began her career there in 2003 and was promoted to deputy CFO in 2016 before becoming CFO in 2017.

Dec 19, 2019

Laboratory for Advanced Medicine: Aarif Nakhooda

Laboratory for Advanced Medicine has appointed Aarif Nakhooda as CFO. He was most recently CFO of Amazon Retail Singapore. He also previously served as head of finance for Amazon Prime worldwide and Amazon Prime Transportation. Prior to joining Amazon, he worked in transaction advisory services for Ernst & Young. Based in Irvine, California, Laboratory for Advanced Medicine is commercializing tests for the early detection of cancer from a blood draw by using AI technology to identify cfDNA methylation patterns.

Dec 18, 2019

XCR Diagnostics: Chuck Morrison

XCR Diagnostics has appointed Chuck Morrison to its board of directors. Morrison was a director at GenePOC and aided in the acquisition of that firm by Meridian Bioscience earlier this year. He earlier was a director of business development at PerkinElmer.

Dec 16, 2019

Grail: Gautam Kollu

Grail has appointed Gautam Kollu as chief commercial officer. Kollu previously served as VP of global market development at Illumina. Before Illumina, Kollu served as VP of marketing, medical affairs, and business development at Natera. Prior to Natera, he served as VP of commercial at Exelixis and worked in several marketing and commercial roles at Genentech. 

Dec 12, 2019

Viracor Eurofins: Karina Eterovic

Viracor Eurofins has appointed Karina Eterovic as the director of research and development for oncology diagnostics for Eurofins' US clinical diagnostics group. Eterovic joined the firm from MD Anderson Cancer Center, where she was associate professor and director of the cancer genomics laboratory and drove the implementation of precision medicine. Further, at MD Anderson she established a genomics laboratory for NGS research projects, enabling the discovery and identification of new biomarkers for personalized cancer care. 

Dec 12, 2019

Digital Pathology Association: Michael Rivers

The Digital Pathology Association announced Michael Rivers has been named its new president, effective Jan. 1, 2020. Rivers is currently the vice president of Roche Digital Pathology and has been the head of the division since 2015, leading the digital pathology teams in California and Arizona. He joined Roche Tissue Diagnostics in 2006. Rivers will replace outgoing DPA President Marilyn Bui. 

Dec 09, 2019

Roche: Andreas Oeri, John Bell

Roche announced Andreas Oeri will retire from the company's board of directors in 2020, to be replaced by Jörg Duschmalé. Oeri was previously chairman of the company's corporate governance and sustainability committee. Also, the company said that John Bell will not stand for reelection to the board in 2020, and the board has proposed Patrick Frost, CEO of the Swiss Life Group, for his replacement. 

Additionally, Gottlieb Keller, Roche's general counsel, a member of the corporate executive committee, and the board's secretary, will retire in March 2020 after 35 years at the company. Claudia Böckstiegel, who is currently the head of legal of Roche's diagnostics division, will take over as general counsel. On April 1, 2020, she will also become a member of the Enlarged Corporate Executive committee. Annette Luther, the current general manager of Roche Diagnostics International, will be the new secretary to the board. 

Pages